Novartis

Granite Bio is a biotechnology company focused on developing novel monoclonal antibodies aimed at treating inflammatory, autoimmune, and fibrotic disorders. The company specializes in creating therapeutic antibodies that deplete pathogenic cells and selectively target key biological processes associated with these diseases. By concentrating on these advanced treatments, Granite Bio contributes to the broader fields of biotechnology, pharmaceuticals, and diagnostics, ultimately seeking to improve patient outcomes in complex medical conditions.

Anthos Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapies for cardiovascular and metabolic diseases. Founded in 2018, the company specializes in treatments targeting Factor XI and XIa, essential components of the intrinsic coagulation pathway. Its lead product, MAA868, is an antibody designed to provide an anti-thrombotic effect, allowing healthcare professionals to prevent various thrombotic diseases while minimizing the risk of bleeding. By advancing long-acting treatment options, Anthos Therapeutics aims to improve care for patients suffering from cardiovascular conditions, representing a significant advancement over conventional therapies.

Rhygaze is focused on developing a novel gene therapy aimed at restoring vision in patients affected by diseases that lead to blindness. The company's innovative technology specifically targets cone cells, which are crucial for light detection but may lose sensitivity due to various conditions. By delivering a light-sensor gene directly to these compromised cone cells, Rhygaze seeks to repair their ability to detect light, thereby offering potential vision restoration solutions for individuals suffering from blindness.

Alesta Therapeutics is engaged in developing innovative therapies aimed at treating cancer by targeting chronic stress response pathways. The company focuses on small molecule biotech programs that address synthetic lethal metabolic dependencies essential for cancer cell survival. By targeting specific control mechanisms involved in these pathways, Alesta Therapeutics aims to provide new therapeutic approaches that can effectively disrupt the growth of cancer cells, thereby enhancing treatment options for patients.

Citryll is a private pharmaceutical company based in Oss, The Netherlands, founded in 2015. The company focuses on developing drugs aimed at treating autoimmune diseases and other human health conditions. Citryll's innovative approach involves the manipulation of the formation, function, and clearance of neutrophil extracellular traps (NETs) that are influenced by the protein citrullination pathway, specifically through the action of Peptidylarginine Deiminase (PAD) enzymes. This research supports medical professionals in addressing various serious conditions, including lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis, and organ damage resulting from sepsis.

Kate Therapeutics is a biotechnology company dedicated to developing adeno-associated virus (AAV)-based gene therapies for genetically defined muscle and heart diseases. The company employs advanced technology platforms to enhance tissue-specific delivery and gene regulation, overcoming significant challenges associated with current gene therapies. By utilizing innovative capsids, Kate Therapeutics achieves superior muscle transduction and effectively de-targets the liver, allowing for more efficient tissue transduction at lower viral doses. This approach addresses key limitations in muscle gene delivery, aiming to improve treatment outcomes for patients with muscle and heart conditions.

LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease and other triplet repeat diseases.

ONL Therapeutics is a biopharmaceutical company focused on developing innovative therapeutics to protect and improve vision in patients with retinal diseases and conditions. Founded in 2006 and headquartered in Ann Arbor, Michigan, the company specializes in creating photoreceptor protective agents that target the FAS apoptotic pathway. Its drug programs aim to safeguard photoreceptors, thereby enhancing outcomes for patients undergoing surgeries related to retinal detachment and other serious vision-threatening issues. Through its research and development efforts, ONL Therapeutics seeks to provide effective solutions for preserving sight and improving the quality of life for individuals affected by these conditions.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

Borealis Biosciences is a discovery-stage biotechnology company focused on developing next-generation RNA-based medicines specifically for kidney diseases. The company utilizes its expertise in molecular and cellular biology, chemistry, and analytical capabilities to identify target opportunities within different patient subsets affected by kidney conditions. By refining methods for delivering RNA medicines to specific cell types, Borealis Biosciences aims to tackle significant unmet medical needs in the treatment of kidney diseases.

Dren Bio is a biotechnology company that specializes in protein engineering technologies designed to target and deplete pathogenic cells, protein aggregates, and other disease-causing agents. With a focus on hematologic neoplasms, solid cancers, autoimmune disorders, and diseases related to protein aggregation, the company aims to provide innovative solutions for healthcare professionals in their efforts to combat various serious diseases. Operating under a holding company model, Dren Bio develops multiple projects as standalone assets, seeking to create value through its diverse portfolio of biotechnology initiatives.

Rhygaze is focused on developing a novel gene therapy aimed at restoring vision in patients affected by diseases that lead to blindness. The company's innovative technology specifically targets cone cells, which are crucial for light detection but may lose sensitivity due to various conditions. By delivering a light-sensor gene directly to these compromised cone cells, Rhygaze seeks to repair their ability to detect light, thereby offering potential vision restoration solutions for individuals suffering from blindness.

CatalYm GmbH, founded in 2016 and based in Munich, Germany, is a biotechnology company focused on developing innovative immunotherapies for cancer patients. The company has identified GDF-15 as a key regulator of the immune system within the tumor microenvironment. By neutralizing GDF-15, CatalYm aims to enhance the immune response against solid tumors, potentially leading to meaningful clinical outcomes. Its CTL-002 program is designed to demonstrate clinical proof-of-concept across multiple solid tumor indications, offering the prospect of expanding treatment options for cancer patients. Through its approach, CatalYm seeks to transform the tumor microenvironment, making tumors more accessible to the immune system and improving both survival rates and quality of life for patients.

Mariana Oncology is a biotechnology company focused on developing radiopharmaceuticals designed to target cancer cells using radioactive drugs. The company leverages expertise in ligand discovery, radiochemistry, and radiobiology, along with oncology translational and clinical research, to create a diverse pipeline aimed at treating various solid tumor types. By advancing the use of radiomedicines, Mariana Oncology seeks to enhance treatment options for medical professionals in their fight against cancer.

FundaMental Pharma is a neuroscience company focused on developing innovative treatments for neurological diseases at the preclinical stage. The company creates neuroprotective molecular spacers aimed at preventing neurodegeneration in the brain. Utilizing peptides and gene therapy, FundaMental Pharma specializes in diagnosing polymorphisms and is dedicated to developing a novel class of drugs that target untreatable neurological conditions. Through its research, the company seeks to provide pharmacological solutions for patients suffering from various challenging neurological disorders.

Capstan Therapeutics is a biotechnology company focused on enhancing the therapeutic potential of in vivo RNA-based therapies. It develops proprietary targeted delivery systems, including targeted lipid nanoparticles, to improve the efficacy and control of dosage in engineered cell therapies. This innovative platform aims to address a variety of diseases, particularly in the fields of oncology, fibrosis, and inflammation, where there are significant unmet clinical needs. By advancing precision in vivo cell engineering, Capstan Therapeutics seeks to create transformative therapeutics that can offer new solutions for patients facing these challenging conditions.

Enterprise Therapeutics, established in 2014 and headquartered in Brighton, UK, is a drug discovery company focused on developing therapies for respiratory diseases. Its primary focus is on chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company aims to create novel treatments that target the underlying mechanisms of mucus congestion, reducing lung infections and enhancing patients' quality of life.

Aravax is an early-stage biotechnology company based in Melbourne, Australia, dedicated to developing a safe and effective treatment for peanut allergies. Founded in May 2015 through the acquisition of intellectual property from Alfred Health and Monash University, Aravax employs proprietary technology aimed at resetting the immune system to tolerate peanuts without triggering allergic reactions. The company's innovative approach seeks to eliminate the risk of life-threatening responses to peanuts, allowing patients to undergo treatment and potentially overcome mild symptoms such as itchiness, rash, and gastrointestinal upset.

Calypso Biotech SA is an immunotherapy biotechnology company based in Plan-les-Ouates, Switzerland, founded in 2013 as a spin-off from Merck Serono. The company specializes in discovering and developing monoclonal antibodies aimed at treating immune pathologies, particularly for conditions with significant unmet medical needs, including severe gastrointestinal diseases. Calypso Biotech operates as a semi-virtual organization, leveraging a highly experienced management team with expertise in drug development. The company focuses on creating substantial value for investors through a portfolio of unique proprietary antibody candidates designed to control homeostasis and improve treatment outcomes for patients.

SanReno Therapeutics specializes in the development, manufacturing, and commercialization of therapies for kidney diseases in several regions including the People's Republic of China, Hong Kong, Macau, Taiwan, and Singapore. Established through a joint venture involving Chinook Therapeutics, Frazier Healthcare Partners, and Pivotal bioVenture Partners China, the company is dedicated to researching and producing innovative biotech solutions aimed at improving the quality of life for patients suffering from kidney-related conditions.

AstronauTx is a biotechnology company focused on developing treatments for Alzheimer's disease and other neurodegenerative conditions. The company aims to restore the normal functioning of astrocytes, which are crucial cells in the brain that support neuronal activity, metabolism, and the integrity of the blood-brain barrier. In conditions such as dementia, astrocytes can become dysfunctional, leading to neurotoxicity and exacerbating disease progression. By targeting astrocyte homeostasis, AstronauTx seeks to enable healthcare professionals to effectively address the underlying mechanisms of neurotoxicity associated with these diseases, ultimately improving treatment options for patients suffering from dementia and related disorders.

Hyku is a biotechnology company focused on developing small molecule therapeutics that target disease-causing proteins through precise covalent binding. Utilizing its innovative platform, Hyku identifies molecules that covalently bind to non-cysteine amino acids, facilitating the creation of novel therapies. These therapies aim to address significant challenges in drug development, including issues related to selectivity, druggability, and resistance. By pushing the boundaries of covalent medicine, Hyku seeks to create effective treatments that can improve patient outcomes and advance the field of therapeutic development.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments tailored to patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of therapies that address unmet needs in cancer care. Fore Biotherapeutics conducts research to replicate naturally occurring mutations in vitro, allowing for the assessment of their impact on cellular signaling pathways and responses to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharma companies broaden the patient subgroups that may benefit from existing cancer therapies.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company's platform generates, analyzes, and integrates data to provide a comprehensive approach aimed at reducing the overall cost of care. By optimizing healthcare medications and utilization, Octave enables pharmaceutical companies to enhance the entire lifecycle of drug discovery, clinical trials, and post-marketing processes through the use of real-world evidence. This innovative approach seeks to improve patient outcomes while streamlining healthcare practices.

DTx Pharma, LLC is a biotechnology company focused on developing and commercializing fatty acid-conjugated peptide therapeutics for patients with rare and chronic diseases. The company specializes in RNA-based therapeutics, utilizing a delivery technology platform that enhances the distribution of nucleic acid drugs to various tissues and organ systems beyond the liver. This innovative approach addresses limitations associated with previous-generation RNA delivery methods, such as poor pharmacokinetics and inadequate cellular uptake. DTx Pharma's products target conditions including retinitis pigmentosa, Duchenne muscular dystrophy, and central nervous system disorders. Founded in 2017 and based in San Diego, California, DTx Pharma aims to provide personalized treatment options across multiple therapeutic areas.

Tagworks Pharmaceuticals is a privately held biotech company based in the Netherlands, established in 2011 as a spin-out from Philips Healthcare. The company focuses on developing innovative in vivo chemistry to enhance the effectiveness of cancer therapies and to facilitate novel companion diagnostics. Operating from the Radboud University Medical Center in Nijmegen, Tagworks specializes in antibody-based imaging and therapy technologies. Its proprietary approach allows for the selective chemical manipulation of tagged antibodies in vivo, which improves the efficacy of established methods like radioimmuno-imaging and antibody-drug conjugates. This technology enables medical professionals to conduct imaging with significantly reduced radiation exposure for patients.

Chinook Therapeutics, Inc. is a clinical-stage biotechnology company based in Seattle, Washington, that specializes in the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead program is atrasentan, an investigational endothelin receptor antagonist currently prepared for Phase III trials targeting IgA nephropathy and other primary glomerular diseases. In addition to atrasentan, Chinook is developing BION-1301, an investigational anti-APRIL monoclonal antibody evaluated in a Phase Ib trial for IgA nephropathy, and CHK-336, a preclinical candidate aimed at treating an undisclosed ultra-orphan kidney disease. Chinook Therapeutics is also engaged in research programs addressing other rare and severe chronic kidney conditions, including polycystic kidney disease.

Flare Therapeutics is a biotechnology company focused on developing small molecule medicines by exploring the biology of transcription factors. The company aims to identify 'switch sites,' which are druggable regions crucial for regulating transcription factors, to target mutations associated with various diseases. Flare's innovative approach has advanced its drug discovery efforts, resulting in a promising pipeline of programs that primarily address well-established transcription factors. Initially concentrating on precision oncology, the company's research also holds potential applications in neurology, rare genetic disorders, immunology, and inflammation. By leveraging insights from its scientific founders, Flare Therapeutics seeks to transform the treatment landscape for cancer patients and other disease areas.

Mediar Therapeutics is a pre-clinical stage biotechnology company based in Cambridge, Massachusetts, focused on developing antibody-based therapeutics for the treatment of fibrosis. Founded in 2019, the company aims to provide innovative solutions by targeting key fibrotic mediator proteins that contribute to the development of fibrosis in chronically damaged organs. Through its research and development efforts, Mediar seeks to enable medical practitioners to halt and potentially reverse critical fibrosis and related conditions, addressing a significant unmet need in the field of fibrotic diseases.

CatalYm GmbH, founded in 2016 and based in Munich, Germany, is a biotechnology company focused on developing innovative immunotherapies for cancer patients. The company has identified GDF-15 as a key regulator of the immune system within the tumor microenvironment. By neutralizing GDF-15, CatalYm aims to enhance the immune response against solid tumors, potentially leading to meaningful clinical outcomes. Its CTL-002 program is designed to demonstrate clinical proof-of-concept across multiple solid tumor indications, offering the prospect of expanding treatment options for cancer patients. Through its approach, CatalYm seeks to transform the tumor microenvironment, making tumors more accessible to the immune system and improving both survival rates and quality of life for patients.

Orionis Biosciences is a biotechnology company focused on early-stage drug discovery and development, particularly targeting oncology and immunotherapies. Headquartered in Waltham, Massachusetts, with additional research facilities in Ghent, Belgium, the company utilizes a range of innovative technologies to create conditionally active drug modalities aimed at treating diseases with significant unmet medical needs. By inducing molecular proximity and cooperativity, Orionis enhances drug potency and precision, allowing for novel target access. Their approach facilitates the development of a diverse pipeline of drug candidates, including therapies that engage both adaptive and innate immune systems. The company collaborates with strategic partners, including VIB in Belgium, and is supported by a team of seasoned entrepreneurs and scientists, as well as a transatlantic network of investors.

Capstan Therapeutics is a biotechnology company focused on enhancing the therapeutic potential of in vivo RNA-based therapies. It develops proprietary targeted delivery systems, including targeted lipid nanoparticles, to improve the efficacy and control of dosage in engineered cell therapies. This innovative platform aims to address a variety of diseases, particularly in the fields of oncology, fibrosis, and inflammation, where there are significant unmet clinical needs. By advancing precision in vivo cell engineering, Capstan Therapeutics seeks to create transformative therapeutics that can offer new solutions for patients facing these challenging conditions.

Aktis Oncology is a biotechnology company focused on developing targeted radiopharmaceuticals for the treatment of various solid tumor cancers. The company has created proprietary platforms that generate tumor-targeting agents optimized for alpha radiotherapy. These agents are engineered to achieve high penetration into tumors and prolonged residence time, allowing for effective tumor elimination while reducing side effects associated with treatment. Additionally, Aktis Oncology's innovative approach enables clinicians to visualize and confirm target engagement before administering therapeutic radioisotopes, enhancing the precision of cancer treatment.

Kedalion Therapeutics Inc. is a biotechnology company based in Menlo Park, California, specializing in the development and commercialization of innovative topical ophthalmic therapies. Founded in 2015, the company utilizes its proprietary AcuStream platform technology to deliver topical drugs to the eye with high precision and accuracy. This novel, digitally connected, electromechanical delivery device significantly reduces the required dosage by up to 80% compared to traditional eye drops, while enhancing patient comfort and minimizing side effects. Kedalion's approach aims to meet the unmet needs of patients by providing a user-friendly device that improves the administration of ocular therapies, thereby benefiting both healthcare professionals and patients through increased efficiency and comfort.

Alladapt Immunotherapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for food allergies. Founded in 2018 and based in Menlo Park, California, the company is advancing its lead program, ADP101, which aims to provide a broad-spectrum oral immunotherapy treatment. This innovative drug targets the mitigation, treatment, and prevention of food allergies caused by single or multiple proteins from a wide range of common allergens. Through its research and development efforts, Alladapt Immunotherapeutics seeks to enable healthcare providers to effectively address the challenges faced by patients with various food allergies.

Deciphex Limited, founded in 2017 and based in Dublin, Ireland, specializes in developing digital pathology software applications aimed at enhancing diagnostic workflows through artificial intelligence. The company offers two primary platforms: Patholytix and Diagnexia. Patholytix is designed for preclinical and toxicologic pathology, aiding pharmaceutical and clinical research organizations in optimizing safety assessments and accelerating drug development. Diagnexia facilitates rapid diagnostics by connecting global subspecialty pathologists, thereby addressing backlog issues. Both platforms automate routine tasks, allowing pathologists to concentrate on more complex cases, which ultimately leads to faster and more reliable diagnoses. Through its innovative approach, Deciphex is committed to improving patient outcomes and advancing healthcare delivery.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

Splice Bio is a biotechnology company based in Barcelona, Spain, focused on developing innovative gene therapies using its proprietary intein platform technology. Founded in 2012 and originally named Proteodesign, S.L., the company aims to address the needs of patients suffering from incurable genetic diseases. The intein platform, developed from research in the Muir Lab at Princeton University, seeks to overcome two significant limitations of traditional adeno-associated virus (AAV) therapies: it enhances the capacity for larger gene delivery and broadens the range of tissues that can be targeted for treatment.

Koneksa Health Inc. is a healthcare data analytics company focused on enhancing clinical studies and disease research through the use of remotely generated patient data. The company's software, Koneksa Compare, facilitates the collection, visualization, and analysis of patient-generated data, incorporating emerging technologies such as bio-sensors, activity trackers, and mobile-based questionnaires. This platform allows pharmaceutical and biotech companies, as well as academic researchers, to make informed decisions and regulatory claims based on objective data. Koneksa also provides biometric devices that generate electronic clinical outcome assessments and offers a dashboard for monitoring patient engagement, which includes reminders for study subjects. Founded in 2013 and headquartered in New York, Koneksa has an additional office in London, United Kingdom.

ImmPACT Bio USA Inc. is a cell therapy company focused on developing engineered T-cells specifically designed to target and treat solid tumors. By utilizing advanced technology, the company aims to create chimeric antigen receptor (CAR) T-cell therapies that exhibit tumor specificity, allowing them to induce cytotoxicity only when interacting with tumor cells while sparing healthy tissues. This selective targeting mitigates the safety risks commonly associated with existing CAR-T therapies, providing a promising approach to cancer treatment that enhances efficacy and reduces potential harm to noncancerous cells.

Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.

Anaveon AG is a biopharmaceutical company based in Bottmingen, Switzerland, founded in 2017. The company specializes in developing biologics that modulate cytokine functions, particularly focusing on next-generation IL-2 complexes. These complexes selectively enhance effector T cell functions, acting as effective immune adjuvants with a broad therapeutic window. Anaveon's innovative compounds demonstrate significant preclinical efficacy against cancer, both as standalone treatments and in combination with other therapies. The company's mission is to transform cytokines into life-saving treatments for patients suffering from various diseases characterized by immune system dysfunction. Through its targeted approach, Anaveon aims to provide substantial therapeutic benefits to cancer patients and others affected by immune pathology.

LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease and other triplet repeat diseases.

Kedalion Therapeutics Inc. is a biotechnology company based in Menlo Park, California, specializing in the development and commercialization of innovative topical ophthalmic therapies. Founded in 2015, the company utilizes its proprietary AcuStream platform technology to deliver topical drugs to the eye with high precision and accuracy. This novel, digitally connected, electromechanical delivery device significantly reduces the required dosage by up to 80% compared to traditional eye drops, while enhancing patient comfort and minimizing side effects. Kedalion's approach aims to meet the unmet needs of patients by providing a user-friendly device that improves the administration of ocular therapies, thereby benefiting both healthcare professionals and patients through increased efficiency and comfort.

Mekonos Inc. specializes in the design, development, and production of gene and cell therapies, focusing on a proprietary cell-engineering platform that utilizes advanced silicon technology. Founded in 2017 and based in San Francisco, the company has created an integrated system-on-a-chip, which incorporates micro-electromechanical systems (MEMS) to enable the precise injection of single cells using nanoneedles in a parallel architecture. This innovative approach aims to industrialize genome editing and enhance drug discovery and development processes. Mekonos' technology allows for scalable and reliable manufacturing of engineered therapies aimed at addressing genetic diseases, including various forms of cancer, and supports healthcare providers in delivering diverse therapeutic molecules across multiple cell types.

XOMA Corporation is a biotechnology company focused on the discovery and development of therapeutic candidates, primarily in the fields of monoclonal antibodies and innovative drug technologies. With a robust pipeline, the company is developing proprietary product candidates such as X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody for Type 2 diabetes; and therapies targeting metastatic melanoma and renal cell carcinoma. XOMA also has initiatives aimed at addressing unmet medical needs related to hyperparathyroidism. In addition to its own product development, the company licenses antibody discovery and optimization technologies and collaborates with major pharmaceutical firms, including Novartis and Takeda, to enhance clinical development efforts. Founded in 1981 and headquartered in Emeryville, California, XOMA is positioned at the forefront of biopharmaceutical innovation, contributing to advancements in healthcare.

Dunad Therapeutics is a biopharmaceutical company dedicated to developing innovative targeted protein degradation therapies. The company utilizes a small molecule platform that induces the selective degradation of disease-causing and often difficult-to-target proteins by directly modulating their stability and conformation. This approach offers a novel molecular strategy that is adaptable and operates through a mechanism of action that is not limited to specific target classes, distinguishing it from existing targeted protein degradation technologies. By focusing on oral therapies, Dunad Therapeutics aims to provide effective treatment options for challenging diseases.

Capstan Therapeutics is a biotechnology company focused on enhancing the therapeutic potential of in vivo RNA-based therapies. It develops proprietary targeted delivery systems, including targeted lipid nanoparticles, to improve the efficacy and control of dosage in engineered cell therapies. This innovative platform aims to address a variety of diseases, particularly in the fields of oncology, fibrosis, and inflammation, where there are significant unmet clinical needs. By advancing precision in vivo cell engineering, Capstan Therapeutics seeks to create transformative therapeutics that can offer new solutions for patients facing these challenging conditions.

Exo Therapeutics, Inc. is a drug discovery and development company focused on addressing intractable pharmaceutical targets. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary ExoSight platform to develop a pipeline of drug candidates. These candidates are designed to bind to exosites and unique binding pockets, allowing for the reprogramming of enzyme activity to achieve targeted therapeutic effects. This innovative approach aims to provide robust treatments in areas such as oncology and inflammation, while also minimizing potential side effects for patients. By employing a precise and selective methodology, Exo Therapeutics is positioned to unlock new therapeutic possibilities for a variety of diseases.

Expansion Therapeutics is a drug discovery and development company focused on creating small molecule medicines for RNA-mediated diseases. The company specializes in developing novel RNA-targeted drug candidates that have the potential to treat a wide range of severe health conditions. By leveraging its innovative technology, Expansion Therapeutics aims to provide effective treatment options for patients suffering from these challenging diseases.

Arctos Medical is a spin-off from the University of Bern that focuses on developing optogenetic therapies to address common forms of blindness, particularly those caused by inherited retinal dystrophies (IRDs). Unlike traditional approaches that target rare genetic eye diseases, Arctos Medical's innovative gene therapy aims to enhance the quality of visual information transmitted to the brain, thereby offering potential treatments for patients experiencing complete vision loss. Through its research and development efforts, the company seeks to improve the lives of individuals affected by various forms of blindness.

Immunitas Therapeutics, Inc. is focused on developing targeted therapies for cancer patients through innovative single-cell analyses. Founded in 2019 and based in Cambridge, Massachusetts, the company utilizes a single-cell sequencing platform to explore the biology of immune cells within human tumors. This approach allows Immunitas to identify novel drug targets rooted in human biology and create key biomarkers that assist in selecting patients who may benefit from their therapies. By translating laboratory findings into clinical applications, Immunitas aims to address longstanding challenges in oncology and improve treatment options for complex cancers. The company is advancing multiple programs toward early human studies, leveraging expertise in antibody discovery and engineering to develop effective treatments.

GentiBio, Inc. is a biotherapeutics company focused on developing engineered regulatory T cells (EngTregs) aimed at treating autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and headquartered in Boston, Massachusetts, with additional locations in Israel and Seattle, GentiBio utilizes a proprietary platform that combines autologous and allogeneic EngTregs technologies. This innovative approach is designed to restore immune tolerance and address limitations present in current regulatory T-cell therapies. By targeting the underlying causes of diseases related to immune system dysfunction, GentiBio aims to provide effective therapeutic solutions for conditions that arise from immune system overshooting or malfunctioning. The company was co-founded by experts in Treg biology and synthetic immunology, positioning it at the forefront of this emerging field.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2015, the company is dedicated to creating first-in-class therapies aimed at selectively killing cancer cells. Artios's product pipeline features several promising programs, including a focus on DNA polymerase theta (Polθ), which plays a crucial role in DNA repair processes. Additionally, the company is advancing an in-licensed program that targets a newly identified protein linked to DDR and is developing a novel treatment aimed at DNA nucleases involved in these pathways. Artios collaborates with Cancer Research Technology and prominent DNA repair researchers globally to enhance its research and development efforts.

Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing novel cancer therapies that target monoPARP proteins, which are essential regulators of cancer survival mechanisms. Established in 2015, Ribon is leveraging insights from its scientific founders and an experienced management team to create a proprietary drug discovery platform aimed at understanding the molecular actions and biological functions of monoPARPs. This platform enables the development of small molecule inhibitors designed to disrupt cancer cells' abilities to withstand stress, potentially leading to innovative treatments for cancer and other diseases. The company is supported by notable life science investors, positioning it for growth in the biopharmaceutical sector.

Cellerys, headquartered in Zurich, Switzerland, is a biotechnology company focused on developing a novel therapy for multiple sclerosis (MS). Their proprietary platform aims to induce immune tolerance in MS patients by coupling autologous red blood cells with specific peptides, a process designed to potentially treat MS through antigen-specific tolerance induction. The company's semi-automatic good manufacturing practice process streamlines this procedure, facilitating its application in clinical settings and advancing the care of autoimmune disease patients.

Soteria Biotherapeutics, Inc., founded in 2018 and based in San Francisco, California, focuses on developing innovative immunotherapies for cancer treatment. The company is creating a new generation of conditionally active bispecific T-cell engaging antibodies specifically aimed at treating solid tumors. Utilizing its advanced T-LITE™ platform, Soteria enables small molecule-dependent activation of these bispecific antibody therapies, which facilitates safer and more effective treatment options. This approach allows for pulsatile activity, resulting in reduced side effects and the potential for higher dosing, thereby improving the overall therapeutic experience for patients.

Aktis Oncology is a biotechnology company focused on developing targeted radiopharmaceuticals for the treatment of various solid tumor cancers. The company has created proprietary platforms that generate tumor-targeting agents optimized for alpha radiotherapy. These agents are engineered to achieve high penetration into tumors and prolonged residence time, allowing for effective tumor elimination while reducing side effects associated with treatment. Additionally, Aktis Oncology's innovative approach enables clinicians to visualize and confirm target engagement before administering therapeutic radioisotopes, enhancing the precision of cancer treatment.

Amphista Therapeutics Limited is a biopharmaceutical company based in Motherwell, United Kingdom, established in 2017. The company specializes in targeted protein degradation technology to develop innovative cancer therapeutics. Amphista's approach focuses on harnessing the body's natural processes to selectively and efficiently degrade disease-causing proteins, aiming to create first-in-class treatments. By advancing novel methodologies in targeted protein degradation, Amphista seeks to improve therapeutic efficacy and modulate protein abundance linked to disease progression, ultimately enhancing patient outcomes in oncology.

TScan Therapeutics is a biopharmaceutical company dedicated to discovering and developing innovative T cell receptor (TCR) engineered therapies to combat various cancers. Based in Waltham, Massachusetts, the company focuses on TCR-T therapies for both liquid cancers and solid tumors. Its lead candidates, TSC-100 and TSC-101, are designed to address hematologic malignancies, specifically targeting residual leukemia and preventing relapse after hematopoietic stem cell transplantation. In addition, TScan is advancing a multiplexed TCR-T therapy program aimed at treating a range of solid tumors. The company's proprietary platform identifies clinically relevant T cell antigens and minimizes off-target effects, enhancing the precision of its therapies. Founded in 2018, TScan Therapeutics is committed to improving outcomes for patients with serious diseases.

SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. Founded in 1999, the company has developed advanced technologies such as SOMAmers, slow off-rate modified aptamers that specifically bind to target proteins, and the SOMAscan platform, which facilitates comprehensive protein measurement. This innovative approach allows for the analysis of protein biomarker signatures, significantly enhancing the understanding of health and disease beyond traditional genomic methods. SomaLogic's products are utilized in a variety of applications, including diagnostics for conditions in oncology, neurology, and cardiovascular and metabolic diseases, as well as in drug discovery and development. The company also offers diagnostic tests and protein measurement solutions for life science and biopharma researchers, contributing to advancements in medical science.

Cadent Therapeutics, Inc. is a precision neuroscience company focused on developing innovative therapies for serious neurological and psychiatric disorders. Founded in 2010 and based in Cambridge, Massachusetts, the company specializes in small molecule therapeutics that target NMDA receptors to address conditions such as depression, schizophrenia, Rett syndrome, and other cognitive and movement disorders. Cadent's approach combines target specificity, patient selection, and drug design to create allosteric modulators that can enhance neuronal firing regularity and restore brain rhythms. By leveraging novel quantitative endpoints, Cadent aims to develop first-in-class medications that improve cognitive and motor functions in patients, ultimately enhancing clinical outcomes for those suffering from various neurological diseases.

Exo Therapeutics, Inc. is a drug discovery and development company focused on addressing intractable pharmaceutical targets. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary ExoSight platform to develop a pipeline of drug candidates. These candidates are designed to bind to exosites and unique binding pockets, allowing for the reprogramming of enzyme activity to achieve targeted therapeutic effects. This innovative approach aims to provide robust treatments in areas such as oncology and inflammation, while also minimizing potential side effects for patients. By employing a precise and selective methodology, Exo Therapeutics is positioned to unlock new therapeutic possibilities for a variety of diseases.

Faze Medicines is a biotechnology company founded in 2020 and located in Cambridge, Massachusetts. The company focuses on developing small molecule drugs that target the underlying mechanisms of disease pathology, with initial therapeutic efforts directed towards conditions such as amyotrophic lateral sclerosis (ALS) and myotonic dystrophy type 1 (DM1). Faze Medicines employs advanced screening and proteomics techniques to explore biomolecular condensate interaction networks, which aids in the identification and development of novel therapeutics. Through its innovative approach, Faze aims to provide effective treatments for patients suffering from these challenging diseases.

Mekonos Inc. specializes in the design, development, and production of gene and cell therapies, focusing on a proprietary cell-engineering platform that utilizes advanced silicon technology. Founded in 2017 and based in San Francisco, the company has created an integrated system-on-a-chip, which incorporates micro-electromechanical systems (MEMS) to enable the precise injection of single cells using nanoneedles in a parallel architecture. This innovative approach aims to industrialize genome editing and enhance drug discovery and development processes. Mekonos' technology allows for scalable and reliable manufacturing of engineered therapies aimed at addressing genetic diseases, including various forms of cancer, and supports healthcare providers in delivering diverse therapeutic molecules across multiple cell types.

CatalYm GmbH, founded in 2016 and based in Munich, Germany, is a biotechnology company focused on developing innovative immunotherapies for cancer patients. The company has identified GDF-15 as a key regulator of the immune system within the tumor microenvironment. By neutralizing GDF-15, CatalYm aims to enhance the immune response against solid tumors, potentially leading to meaningful clinical outcomes. Its CTL-002 program is designed to demonstrate clinical proof-of-concept across multiple solid tumor indications, offering the prospect of expanding treatment options for cancer patients. Through its approach, CatalYm seeks to transform the tumor microenvironment, making tumors more accessible to the immune system and improving both survival rates and quality of life for patients.

Molecular Partners is a clinical-stage biopharmaceutical company focused on developing innovative therapies for serious diseases, with a primary emphasis on oncology. The company specializes in a unique class of protein therapeutics known as DARPin® therapeutics, which are engineered to be potent, specific, and versatile. Molecular Partners has an extensive product pipeline that is organized into three main areas: ophthalmology, targeting retinal diseases such as wet age-related macular degeneration and diabetic macular edema; oncology, featuring DARPin candidates with novel mechanisms of action, including multi-DARPin compounds; and additional therapeutic areas. Through its research and development efforts, Molecular Partners aims to significantly enhance disease management and patient outcomes.

Rappta Therapeutics Oy is a biopharmaceutical company focused on developing innovative anti-cancer drugs that target protein phosphatase 2A (PP2A), a vital enzyme involved in regulating protein de-phosphorylation and tumor growth. Established in 2019 and headquartered in Helsinki, Finland, with an additional office in the United States, the company is in the lead-optimization stage of creating a first-in-class series of molecules aimed at reactivating this key tumor suppressor. The firm employs proprietary development tools to facilitate rational drug design, aiming to provide therapeutic solutions for various cancer types and select non-oncology conditions.

Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments tailored to patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of therapies that address unmet needs in cancer care. Fore Biotherapeutics conducts research to replicate naturally occurring mutations in vitro, allowing for the assessment of their impact on cellular signaling pathways and responses to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharma companies broaden the patient subgroups that may benefit from existing cancer therapies.

ESCAPE Bio is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies for genetically defined subpopulations affected by neurodegenerative diseases. Founded in 2015 and based in South San Francisco, California, the company aims to improve the lives of patients suffering from conditions such as Alzheimer's disease, Parkinson's disease, and sphingolipid storage disorders. ESCAPE Bio's pipeline includes innovative candidates like ESB1609, a small molecule S1P5 receptor agonist targeting CNS lysosomal storage disorders, and ESB5070, a kinase inhibitor specifically designed for Parkinson's patients with the LRRK2 G2019S variant. Additionally, the company is developing a program aimed at addressing the needs of Alzheimer's patients who carry the ApoE4 risk allele. Through its precision-targeted approach, ESCAPE Bio seeks to provide effective treatment options for individuals with these complex genetic profiles.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

ImmPACT Bio USA Inc. is a cell therapy company focused on developing engineered T-cells specifically designed to target and treat solid tumors. By utilizing advanced technology, the company aims to create chimeric antigen receptor (CAR) T-cell therapies that exhibit tumor specificity, allowing them to induce cytotoxicity only when interacting with tumor cells while sparing healthy tissues. This selective targeting mitigates the safety risks commonly associated with existing CAR-T therapies, providing a promising approach to cancer treatment that enhances efficacy and reduces potential harm to noncancerous cells.

GentiBio, Inc. is a biotherapeutics company focused on developing engineered regulatory T cells (EngTregs) aimed at treating autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and headquartered in Boston, Massachusetts, with additional locations in Israel and Seattle, GentiBio utilizes a proprietary platform that combines autologous and allogeneic EngTregs technologies. This innovative approach is designed to restore immune tolerance and address limitations present in current regulatory T-cell therapies. By targeting the underlying causes of diseases related to immune system dysfunction, GentiBio aims to provide effective therapeutic solutions for conditions that arise from immune system overshooting or malfunctioning. The company was co-founded by experts in Treg biology and synthetic immunology, positioning it at the forefront of this emerging field.

FoRx Therapeutics AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company specializes in the development of innovative therapeutics for cancer treatment, specifically targeting key molecular pathways involved in DNA replication stress. By focusing on these novel pathways, FoRx Therapeutics aims to create first-in-class compounds that offer a new approach to targeted anticancer therapies. Through its research and development efforts, the company seeks to provide effective solutions in the fight against cancer.

Amblyotech, LLC is an Atlanta-based company that specializes in developing electronic media therapies for the treatment of amblyopia and other ocular diseases in both adults and children. Founded in 2013, the company has created a novel application that enhances visual acuity and promotes the establishment of 3D vision, utilizing active gaming and passive video technology with 3D glasses. This innovative approach provides an alternative to traditional treatment methods such as patching, atropine drops, and surgery. Amblyotech's solutions are designed for use on various electronic devices, including tablets, computers, and smartphones. As of April 2020, Amblyotech operates as a subsidiary of Novartis AG.

Akouos, Inc. is a biotechnology company based in Boston, Massachusetts, dedicated to developing gene therapies aimed at restoring, improving, and preserving hearing for individuals affected by various inner ear disorders. Founded in 2016, the company utilizes an innovative platform that includes a proprietary adeno-associated viral vector library and a unique delivery method. Its leading product candidate, AK-OTOF, targets hearing loss resulting from mutations in the OTOF gene. Akouos focuses on genetically-defined patient populations, addressing conditions ranging from single genetic mutations to hearing loss caused by ototoxic drugs and aging. The company has established strategic partnerships with key institutions, including Massachusetts Eye and Ear and Lonza, Inc., to advance its mission of providing precision genetic therapies for sensorineural hearing loss.

TScan Therapeutics is a biopharmaceutical company dedicated to discovering and developing innovative T cell receptor (TCR) engineered therapies to combat various cancers. Based in Waltham, Massachusetts, the company focuses on TCR-T therapies for both liquid cancers and solid tumors. Its lead candidates, TSC-100 and TSC-101, are designed to address hematologic malignancies, specifically targeting residual leukemia and preventing relapse after hematopoietic stem cell transplantation. In addition, TScan is advancing a multiplexed TCR-T therapy program aimed at treating a range of solid tumors. The company's proprietary platform identifies clinically relevant T cell antigens and minimizes off-target effects, enhancing the precision of its therapies. Founded in 2018, TScan Therapeutics is committed to improving outcomes for patients with serious diseases.

Arctos Medical is a spin-off from the University of Bern that focuses on developing optogenetic therapies to address common forms of blindness, particularly those caused by inherited retinal dystrophies (IRDs). Unlike traditional approaches that target rare genetic eye diseases, Arctos Medical's innovative gene therapy aims to enhance the quality of visual information transmitted to the brain, thereby offering potential treatments for patients experiencing complete vision loss. Through its research and development efforts, the company seeks to improve the lives of individuals affected by various forms of blindness.

Immunitas Therapeutics, Inc. is focused on developing targeted therapies for cancer patients through innovative single-cell analyses. Founded in 2019 and based in Cambridge, Massachusetts, the company utilizes a single-cell sequencing platform to explore the biology of immune cells within human tumors. This approach allows Immunitas to identify novel drug targets rooted in human biology and create key biomarkers that assist in selecting patients who may benefit from their therapies. By translating laboratory findings into clinical applications, Immunitas aims to address longstanding challenges in oncology and improve treatment options for complex cancers. The company is advancing multiple programs toward early human studies, leveraging expertise in antibody discovery and engineering to develop effective treatments.

Anokion SA is a biotechnology company based in Ecublens, Switzerland, specializing in antigen-specific immune tolerance solutions. As a spin-off from the Ecole Polytechnique Fédérale de Lausanne, Anokion develops innovative immunotherapy aimed at reducing the immunogenicity of therapeutic proteins. The company's platform technology can be applied across a wide range of clinical indications, targeting both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis, and type 1 diabetes. By engineering proteins or antigens for precise therapy, Anokion aims to provide effective treatment options that minimize side effects, thereby improving patient outcomes in the management of autoimmune and allergic diseases.

Adicet Bio is a clinical-stage biotechnology company focused on the design and development of allogeneic gamma delta T cell therapies aimed at treating cancer and other diseases. The company is advancing a pipeline of engineered gamma delta T cells, which are enhanced with chimeric antigen receptors and T cell receptor-like antibodies to improve tumor targeting and bolster the immune response. Its lead product candidate, ADI-001, is a first-in-class therapy that targets CD20 and is being developed for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Additionally, Adicet's pipeline includes ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential applications for other solid tumors and hematological malignancies.

Renovacor, Inc. is a preclinical-stage biopharmaceutical company based in Philadelphia, Pennsylvania, dedicated to developing gene therapies for cardiovascular diseases. Founded in 2013, the company focuses on innovative treatments for dilated cardiomyopathy (DCM), particularly cases caused by mutations in the BAG3 gene. This condition affects over 3 million individuals in the United States, with around 35,000 patients estimated to have BAG3 mutations, classifying it as an orphan disease. Patients with BAG3-associated DCM, often younger and experiencing faster disease progression, currently have limited treatment options, primarily consisting of standard heart failure care. Renovacor's lead program involves a recombinant adeno-associated virus (AAV)-based gene therapy aimed at replacing the defective BAG3 gene, which holds the potential to prevent disease progression and improve outcomes for this vulnerable patient population.

TScan Therapeutics is a biopharmaceutical company dedicated to discovering and developing innovative T cell receptor (TCR) engineered therapies to combat various cancers. Based in Waltham, Massachusetts, the company focuses on TCR-T therapies for both liquid cancers and solid tumors. Its lead candidates, TSC-100 and TSC-101, are designed to address hematologic malignancies, specifically targeting residual leukemia and preventing relapse after hematopoietic stem cell transplantation. In addition, TScan is advancing a multiplexed TCR-T therapy program aimed at treating a range of solid tumors. The company's proprietary platform identifies clinically relevant T cell antigens and minimizes off-target effects, enhancing the precision of its therapies. Founded in 2018, TScan Therapeutics is committed to improving outcomes for patients with serious diseases.

Forendo Pharma Oy is a drug discovery and development company based in Turku, Finland, established in 2013. The company focuses on the tissue-specific regulation of sex hormone effects to address various urological and endocrinological diseases. Its key products include Fispemifene, a selective estrogen receptor modulator designed to treat symptoms of low testosterone in men, and a 17HSD1-inhibitor targeting endometriosis. Forendo Pharma aims to enhance treatment options for both men's and women's health by developing innovative therapies that address unmet medical needs in gynecological conditions, such as endometriosis and polycystic ovarian syndrome.

Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company based in Rehovot, Israel, founded in 2017. The company specializes in developing small molecule therapeutics for rare and aggressive cancers, focusing on genetically defined patient populations. Its lead product candidate is AL101, an intravenous gamma secretase inhibitor currently in Phase II clinical trials for treating recurrent/metastatic adenoid cystic carcinoma in patients with Notch-activating mutations. Additionally, Ayala Pharmaceuticals is developing AL102, an oral gamma secretase inhibitor in Phase I clinical trials for desmoid tumors. The company has a collaboration agreement with Novartis to develop AL102 for multiple myeloma. Ayala's approach involves using bioinformatics and next-generation sequencing to identify and address tumorigenic drivers of cancer, aiming to deliver targeted therapies to underserved patient populations.

Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. It specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. The company's flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on delivering individualized peripheral nerve stimulation. In addition to its work on essential tremor, the company is also developing therapies for other neurological conditions, including Parkinson's disease, as well as applications in psychiatry, cardiology, and autoimmune disorders.

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

Poseida Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapeutics for patients with significant unmet medical needs. The company utilizes non-viral gene engineering technologies to create a pipeline of targeted therapies, including both autologous and allogeneic chimeric antigen receptor T cell (CAR-T) product candidates aimed at treating hematological malignancies and solid tumors. Additionally, Poseida is advancing gene therapies for rare and life-threatening conditions, such as Ornithine transcarbamylase deficiency, methylmalonic acidemia, and various genetic liver diseases. Founded in 2014, Poseida is committed to addressing critical health challenges through its focused research and development efforts.

Anthos Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapies for cardiovascular and metabolic diseases. Founded in 2018, the company specializes in treatments targeting Factor XI and XIa, essential components of the intrinsic coagulation pathway. Its lead product, MAA868, is an antibody designed to provide an anti-thrombotic effect, allowing healthcare professionals to prevent various thrombotic diseases while minimizing the risk of bleeding. By advancing long-acting treatment options, Anthos Therapeutics aims to improve care for patients suffering from cardiovascular conditions, representing a significant advancement over conventional therapies.

Anaveon AG is a biopharmaceutical company based in Bottmingen, Switzerland, founded in 2017. The company specializes in developing biologics that modulate cytokine functions, particularly focusing on next-generation IL-2 complexes. These complexes selectively enhance effector T cell functions, acting as effective immune adjuvants with a broad therapeutic window. Anaveon's innovative compounds demonstrate significant preclinical efficacy against cancer, both as standalone treatments and in combination with other therapies. The company's mission is to transform cytokines into life-saving treatments for patients suffering from various diseases characterized by immune system dysfunction. Through its targeted approach, Anaveon aims to provide substantial therapeutic benefits to cancer patients and others affected by immune pathology.

Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing novel cancer therapies that target monoPARP proteins, which are essential regulators of cancer survival mechanisms. Established in 2015, Ribon is leveraging insights from its scientific founders and an experienced management team to create a proprietary drug discovery platform aimed at understanding the molecular actions and biological functions of monoPARPs. This platform enables the development of small molecule inhibitors designed to disrupt cancer cells' abilities to withstand stress, potentially leading to innovative treatments for cancer and other diseases. The company is supported by notable life science investors, positioning it for growth in the biopharmaceutical sector.

CellforCure is an innovative company specializing in advanced therapy medicinal products, particularly in the field of cell and gene therapy. It operates a cell therapy business that caters to hospitals and clinics, providing essential medicinal products designed to enhance patient care. Through its focus on advanced therapeutic solutions, CellforCure plays a significant role in the evolving landscape of medical treatments, addressing the growing demand for effective and targeted therapies.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients suffering from classical complement-mediated disorders affecting the body, brain, and eye. The company's research is centered around its platform technology that targets classical complement-mediated autoimmune and neurodegenerative diseases associated with the abnormal activation of C1q, a key molecule in the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody intended for intravenous use in treating autoimmune and neurodegenerative disorders. Another candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration aimed at neurodegenerative ophthalmic conditions. The company employs a disciplined, biomarker-driven development strategy to ensure its therapies effectively engage the target at tolerable doses within the intended patient tissues, while also exploring additional indications within both orphan and larger market segments.

Endocyte, Inc. is a biopharmaceutical company focused on developing receptor-targeted therapies for cancer and inflammatory diseases. Headquartered in West Lafayette, Indiana, the company creates innovative small molecule drug conjugates (SMDCs) and companion imaging agents. Among its key products, Vintafolide is in Phase IIb clinical trials for non-small cell lung cancer, while EC1456 and EC1169 are in Phase I trials for advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is developing several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company has established collaborations with Purdue Research Foundation and other organizations to advance its pipeline. Founded in 1995, Endocyte operates as a subsidiary of Novartis AG.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Malvern, Pennsylvania, dedicated to developing innovative therapeutics aimed at enhancing the effectiveness of radiotherapy for cancer patients. The company's lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic currently undergoing Phase III clinical trials for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer. Additionally, GC4419 is being evaluated in Phase IIa trials for the treatment of radiotherapy-induced esophagitis in lung cancer patients. Galera is also advancing another candidate, GC4711, which is in Phase I/II trials for pancreatic and lung cancers. The company's research is focused on targeting oxygen metabolic pathways to improve patient outcomes in radiation therapy, and GC4419 has received Fast Track and Breakthrough Therapy designations from the U.S. Food and Drug Administration.

Coda Biotherapeutics, Inc. is a biotechnology company focused on developing innovative therapies to modulate neuronal activity through its chemogenetic platform. Established in 2014 and based in San Francisco, the company employs gene therapy techniques to modify specific neuronal populations, enabling them to express engineered ligand-gated ion channels that are responsive to a proprietary small molecule. This interaction allows for precise, dose-dependent control of neuronal activity, facilitating the treatment of conditions such as neuropathic pain, epilepsy, and movement disorders. Coda's approach utilizes viral vectors to deliver these engineered neurotransmitter receptors directly to targeted neurons, enhancing the efficiency of treatment for severe nervous system disorders compared to traditional therapies.

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

Forendo Pharma Oy is a drug discovery and development company based in Turku, Finland, established in 2013. The company focuses on the tissue-specific regulation of sex hormone effects to address various urological and endocrinological diseases. Its key products include Fispemifene, a selective estrogen receptor modulator designed to treat symptoms of low testosterone in men, and a 17HSD1-inhibitor targeting endometriosis. Forendo Pharma aims to enhance treatment options for both men's and women's health by developing innovative therapies that address unmet medical needs in gynecological conditions, such as endometriosis and polycystic ovarian syndrome.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycles, which are synthetic short peptides designed to stabilize their structural geometry through two loops. The company primarily targets oncology indications with significant unmet medical needs. Its lead product candidate, BT1718, is a Bicycle Toxin Conjugate currently undergoing Phase I/IIa clinical trials aimed at tumors expressing Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies for Nectin-4. Additionally, Bicycle Therapeutics is developing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to advance programs in areas like anti-infectives and cardiovascular health. Founded in 2009, Bicycle Therapeutics is headquartered in Cambridge, United Kingdom.